Health ❯ Healthcare ❯ Drug Safety

Side Effects

Amyloid-Related Imaging Abnormalities Gastrointestinal Issues GLP-1 Drugs Ocular Issues Patient Dropout Rates Patient Warnings Clinical Study Results Adverse Reactions Differentiation Syndrome Clinical Trials

FDA Clears Enhertu-Perjeta Combo for First-Line HER2-Positive Metastatic Breast Cancer

The decision follows phase 3 results showing a roughly 14-month median progression-free survival advantage over the THP regimen.

Cannabis Extract VER-01 Eases Chronic Low Back Pain in Phase 3 Trial

Pumitamig Shows High Response in First-Line Small Cell Lung Cancer Phase 2